13F Data
13F filer · CIK 1631134

Sofinnova Investments, Inc.

Menlo Park, CA · filing since Q1 2018 · last filing Aug 14, 2026
Reported value
$1.9B
$-696.9M vs prior
Positions
57
New / sold out
13 / 30
Added / reduced
14 / 17
Turnover
15.5%
buys $354.0M · sells $1.3B
Top-10 weight
57.9%

Biggest buys vs Q1 2026

ChangeSecurityShares changeChange %Est. trade value
AddedGenmab A/S+3,292,954+437.7%+$90.5M
NewSeaport Therapeutics Inc+3,564,871–+$77.4M
NewGilead Sciences Inc+343,100–+$43.3M
AddedAnaptysbio Inc+245,283+98.8%+$16.6M
NewIntuitive Surgical IncCALL+40,000–+$15.9M
NewGlobus Med IncCALL+200,000–+$15.8M
NewNurix Therapeutics Inc+524,098–+$12.7M
NewDesign Therapeutics Inc+865,135–+$12.5M
NewFirst Tracks Biotherapeutics+565,199–+$11.4M
NewAbbott Laboratories+122,998–+$11.2M
17 more rows. Subscribe for $29/month to see every row, download the data and use the API.

Biggest sells vs Q1 2026

ChangeSecurityShares changeChange %Est. trade value
Sold outiShares TRPUT-600,000-100.0%$-148.8M
Sold outSPDR Series TrustPUT-1,050,000-100.0%$-134.1M
Sold outAstraZeneca PLC-456,031-100.0%$-89.9M
Sold outInvesco QQQ TRPUT-150,000-100.0%$-86.6M
Sold outiShares TRPUT-475,000-100.0%$-80.2M
ReducedBristol-Myers Squibb Co-1,111,751-55.9%$-64.1M
ReducedJazz Pharmaceuticals PLC-232,986-38.9%$-56.1M
ReducedUltragenyx Pharmaceutical In-1,428,383-45.4%$-47.7M
Sold outUnited Therapeutics CorpPUT-80,300-100.0%$-47.6M
ReducedUnited Therapeutics Corp Del-83,581-52.2%$-45.3M
37 more rows. Subscribe for $29/month to see every row, download the data and use the API.

Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.

Reported value by quarter

Q1 2018: $581.8MQ2 2018: $1.6BQ3 2018: $1.1BQ4 2018: $802.7MQ1 2019: $1.0BQ2 2019: $1.1BQ3 2019: $1.1BQ4 2019: $1.4BQ1 2020: $1.1BQ2 2020: $1.6BQ3 2020: $1.3BQ4 2020: $1.7BQ1 2021: $1.7BQ2 2021: $1.7BQ3 2021: $1.7BQ4 2021: $1.7BQ1 2022: $1.3BQ2 2022: $1.2BQ3 2022: $1.7BQ4 2022: $1.7BQ1 2023: $1.6BQ2 2023: $1.5BQ3 2023: $1.6BQ4 2023: $1.8BQ1 2024: $1.8BQ2 2024: $1.9BQ3 2024: $1.3BQ4 2024: $1.4BQ1 2025: $1.5BQ2 2025: $1.6BQ3 2025: $1.8BQ4 2025: $2.3BQ1 2026: $2.6BQ2 2026: $1.9B
Q1 2018Q2 2026

Holdings · Q2 2026

#SecuritySharesValueWeight
1Natera IncCOM1,550,280$420.8M21.76%
2Vera Therapeutics IncCL A2,793,987$119.9M6.20%
3Genmab A/SSPONSORED ADS4,045,215$111.1M5.74%
4Jazz Pharmaceuticals PLCSHS USD365,341$88.0M4.55%
5Rapport Therapeutics IncCOM1,904,408$79.4M4.10%
6Seaport Therapeutics IncCOM3,564,871$77.4M4.00%
7Arrivent BioPharma IncCOM1,696,752$58.9M3.05%
8Ultragenyx Pharmaceutical InCOM1,717,505$57.3M2.96%
9BioAge Labs IncCOM2,293,788$56.2M2.91%
10Bristol-Myers Squibb CoCOM876,970$50.5M2.61%
47 more rows. Subscribe for $29/month to see every row, download the data and use the API.